title: Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.
abstract: A key step in gene therapy is the efficient transfer of genes in a cell type- and tissue-specific manner. To better understand the mechanism of adeno-associated virus serotype 6 (AAV6) transduction, we used comparative gene analysis (CGA) combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. Subsequent experiments suggested that EGFR is necessary for vector internalization and probably functions as a co-receptor for AAV6.
authors.affiliation: Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, US National Institutes of Health (NIH), Bethesda, Maryland, USA.
authors.forename: Melodie L
authors.initials: ML
authors.lastname: Weller
authors.forename: Panomwat
authors.initials: P
authors.lastname: Amornphimoltham
authors.forename: Michael
authors.initials: M
authors.lastname: Schmidt
authors.forename: Paul A
authors.initials: PA
authors.lastname: Wilson
authors.forename: J Silvio
authors.initials: JS
authors.lastname: Gutkind
authors.forename: John A
authors.initials: JA
authors.lastname: Chiorini
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D000229:Dependovirus / Q000235:genetics / Q000502:physiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D005260:Female; D000077156:Gefitinib; D015870:Gene Expression / Q000235:genetics / Q000502:physiology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D006258:Head and Neck Neoplasms / Q000628:therapy; D007519:Isoantigens; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000628:therapy; D011799:Quinazolines / Q000494:pharmacology; D011991:Receptors, Virus / Q000235:genetics / Q000502:physiology*; D014161:Transduction, Genetic; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D007519:Isoantigens; D011799:Quinazolines; D011991:Receptors, Virus; D020032:Tyrphostins; C067704:neutrophil-specific antigen NA1, human; C101044:RTKI cpd; D066246:ErbB Receptors; D000077156:Gefitinib
references.citation: Mol Ther. 2004 Oct;10(4):671-8
references.pmid: 15451451
references.citation: Hum Gene Ther. 2007 Apr;18(4):344-54
references.pmid: 17430088
references.citation: Nat Med. 2003 Oct;9(10):1306-12
references.pmid: 14502277
references.citation: Trends Microbiol. 2008 May;16(5):208-14
references.pmid: 18406140
references.citation: J Virol. 2006 May;80(10):5082-5
references.pmid: 16641301
references.citation: Hum Gene Ther. 2005 Feb;16(2):178-86
references.pmid: 15761258
references.citation: Br J Cancer. 2002 May 6;86(9):1518-23
references.pmid: 11986789
references.citation: J Virol. 2000 Feb;74(3):1524-32
references.pmid: 10627564
references.citation: Hum Gene Ther. 1996 Nov 10;7(17):2101-12
references.pmid: 8934224
references.citation: Mol Ther. 2008 Jun;16(6):1073-80
references.pmid: 18414476
references.citation: Mol Ther. 2007 Jul;15(7):1323-30
references.pmid: 17440440
references.citation: Hum Gene Ther. 2005 Mar;16(3):381-92
references.pmid: 15812233
references.citation: J Virol. 1998 Dec;72(12):9835-43
references.pmid: 9811719
references.citation: Anticancer Drugs. 2008 Sep;19(8):783-8
references.pmid: 18690089
references.citation: Int J Clin Oncol. 2007 Apr;12(2):99-110
references.pmid: 17443277